araag2/HINT huggingface dataset:
Clinical trial NCT01617135 (phase 2, status: completed)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: cvt-301, placebo, sinemet (carbidopa/levodopa), cvt-301
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 80 years;

          -  Hoehn and Yahr Stage 1-3 in an "on" state;

          -  Require levodopa-containing medication regimen at least 4 times during the waking day;

          -  Experience motor fluctuations with a minimum of 2 hours of average daily "off" time
             per waking day (excluding early morning "off" time) and demonstrate levodopa
             responsiveness;

          -  Are on stable PD medication regimen.

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Previous surgery for PD or plan to have stereotactic surgery during the study period;

          -  History of psychotic symptoms requiring treatment, or suicide ideation or attempt
             within last year;

          -  Adequate lung function as measured by spirometry;

          -  Any significant condition, severe concurrent disease, abnormality or finding that
             would make patients unsuitable or may compromise patient safety.
Clinical trial NCT01578278 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: bepotastine besilate formulation, fluticasone propionate, bepotastine besilate-fluticasone propionate, placebo comparator
SMILES: OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female at least 12 years of age with a demonstrated history of Mountain Cedar
             pollen allergy

        Exclusion Criteria:

          -  No active nasal infection or nasal abnormality that would affect subject safety or
             symptom assessments
Clinical trial NCT00582673 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: afq056, placebo
SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Parkinson's Disease

          -  Patients with L-dopa induced dyskinesia for at least 3 months

          -  Patients with L-dopa treatment for at least 3 years, stable for 1 month minimum

        Exclusion Criteria:

          -  History of severe allergy to food or drugs

          -  Very low or high body weight.

          -  Prior surgery for Parkinson's Disease

          -  Smokers

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00712322 (phase 2, status: terminated)
Conditions: neurogenic detrusor overactivity
ICD codes: R46.3, E27.0
Drugs: darifenacin, darifenacin, darifenacin, darifenacin
SMILES: NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    due to extremely difficult enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients ages 2-15 years

          -  Documented detrusor overactivity associated with a known neurological condition such
             as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline

          -  Using clean intermittent catheterization (CIC) on a regular basis

          -  Participating in a bowel program on a regular basis

          -  Able to swallow the study medication in accordance to the protocol

          -  Patients and/or parent/guardian able to complete the bladder diary and follow the
             study procedures

        Exclusion Criteria:

          -  Treatment with drugs known to significantly affect the urinary bladder and urinary
             bladder outlet function

          -  Fecal impaction. Patients may be included, once this condition has resolved

          -  Clinically significant anatomical abnormalities or acquired disorders of the urinary
             tract

          -  Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet

          -  Symptomatic urinary tract infection unresolved at time of urodynamic study and/or
             completion of bladder diary.

          -  Diabetes insipidus

          -  Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at
             any time during the study

          -  Concomitant diseases, in which the use of darifenacin is contraindicated

          -  History of hypersensitivity to darifenacin or to drugs with similar chemical
             structures

          -  Patients with any physical and cognitive impairment or any other condition which in
             the opinion of the investigator makes the patient unsuitable for inclusion

          -  Female adolescent of child-bearing potential, unless using an acceptable method of
             contraception

          -  Pregnant or nursing (lactating) female adolescents Other protocol-defined
             inclusion/exclusion criteria may apply.
Clinical trial NCT00284050 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ranibizumab 0.3 mg, ranibizumab 0.5 mg, sham injection
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetic macular edema with center involvement in at least one eye

          -  Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening

          -  Laser photocoagulation in the study eye can be withheld for at least 3 months after
             randomization

        Exclusion Criteria:

          -  Patients with uncontrolled systemic or ocular diseases

          -  Have any history of any intraocular surgery in the study eye within the past 6 months
             preceding screening

          -  Conditions that require chronic concomitant therapy with systemic or topical ocular
             corticosteroids

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00657137 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: apricoxib + lapatinib + capecitabine, placebo + lapatinib + capecitabine
SMILES: CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Females with pathologically determined locally advanced or metastatic human epidermal
             growth factor receptor 2 positive (HER2/neu+) breast cancer

          -  Have progressed after treatment with chemotherapy including a taxane and trastuzumab

          -  Must have measurable disease by RECIST

          -  ECOG PS of 0,1, or 2

          -  MUGA scan or echocardiogram results show left ventricular ejection fraction greater
             than or equal to 50%

        Exclusion Criteria:

          -  Radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic
             investigational agents within 4 weeks of initiating study treatment

          -  Evidence of New York Heart Association class III or greater cardiac disease

          -  History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality

          -  History of congenital QT prolongation

          -  Concurrent severe or uncontrolled medical disease

          -  Symptomatic central nervous system metastases

          -  Pregnant or nursing women

          -  Hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-FU,
             sulfonamides, aspirin, or NSAIDs

          -  Severe renal insufficiency

          -  History of upper GI bleeding, ulceration, or perforation- Concurrent use of potent
             CYP3A4 inhibitors and CYP3A4 inducers

          -  Prior treatment with capecitabine

          -  Patients on anti-arrhythmic treatment

          -  Prior lapatinib therapy
Clinical trial NCT01160601 (phase 2, status: completed)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel / carboplatin, bavituximab
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Key Inclusion Criteria:

          -  Adults over 18 years of age with a life expectancy of at least 3 months.

          -  Histologically or cytologically confirmed stage IIIB or stage IV non-squamous NSCLC
             that has not been previously treated with systemic chemotherapy.

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, Version
             1.1).

          -  Adequate hematologic, renal and hepatic function.

          -  PT / INR ≤ 1.5 × ULN, aPTT ≤ 1.5 × ULN and D-dimer ≤ 3 × ULN.

        Key Exclusion Criteria:

          -  Squamous cell, small cell, or mixed histology.

          -  Known history of bleeding diathesis or coagulopathy.

          -  Cavitary tumors or tumors abutting large blood vessels.

          -  Bleeding: Clinically significant bleeding, such as gross hematuria, GI bleeding and
             hemoptysis, within 12 months of Screening.

          -  Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism)
             within 6 months of Screening.

          -  Ongoing therapy with oral or parenteral anticoagulants.

          -  Concurrent estrogens, anti-estrogens or progesterone compounds.

          -  Grade 2 or higher peripheral neuropathy.

          -  Radiotherapy within 2 weeks preceding Study Day 1.

          -  Symptomatic or clinically active brain metastases.

          -  Major surgery within 4 weeks of Study Day 1.

          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease).

          -  Symptomatic coronary artery disease, cerebrovascular accident,transient ischemic
             attack, myocardial infarction, or unstable angina pectoris within 6 months of
             Screening.
Clinical trial NCT00450242 (phase 2, status: terminated)
Conditions: vulvar vestibulitis
ICD codes: N94.810
Drugs: 5% topical lidocaine ointment, placebo cream
SMILES: CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of funding
  
Eligibility criteria:

        Inclusion Criteria:

          -  women with the clinical diagnosis of vvs who have dyspareunia as their primary
             complaint. They must have a current sexual partner.

        Exclusion Criteria:

          -  postmenopausal

          -  pure vaginismus

          -  generalized vulvodynia

          -  pudendal neuralgia

          -  pregnant, breastfeeding

          -  less than 2 months post delivery

          -  diagnosis of dermatologic condition on biopsy

          -  positive fungal culture

          -  currently on treatment for vvs

          -  history of lidocaine treatment for vvs
Clinical trial NCT00177554 (phase 2, status: completed)
Conditions: non-hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: chemotherapy and radioimmunotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Conformed diagnosis of follicular lymphoma, grades 1,2 or 3

          -  No prior chemotherapy

          -  No prior monoclonal antibody therapy

          -  Bulky or symptomatic disease, stage II-IV

          -  Performance status 0-2

        Exclusion Criteria:

          -  Impaired bone marrow reserve

          -  Presence of CNS lymphoma

          -  Serious nonmalignant disease or active infection
Clinical trial NCT00418665 (phase 2, status: completed)
Conditions: myelodysplastic syndromes, thrombocytopenia
ICD codes: D46.9, D46.C, D46.Z, D69.6, D69.49, D69.59, P61.0, D75.82, D69.42, O36.8211
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO)
             classification

          -  Low or Intermediate-1 risk category MDS using the IPSS

          -  Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each
             cycle for at least 4 cycles

          -  Eastern Cooperative Oncology (ECOG) performance status of 0-2

          -  Subjects must be at least 18 years of age or older

        Exclusion Criteria:

          -  Prior exposure to >3 cycles of lenalidomide

          -  Exposure to lenalidomide within the last 30 days

          -  Prior history of leukemia or aplastic anemia

          -  Prior history of stem cell transplantation

          -  Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin)
             unless treated with curative intent and without evidence of disease for 3 years before
             randomization

          -  Active or uncontrolled infections

          -  Unstable angina, congestive heart failure [NYHA > class II], uncontrolled hypertension
             [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year)
             myocardial infarction

          -  History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past
             year

          -  History of venous thrombosis in the past year

          -  Received IL-11 within 4 weeks of screening

          -  Less than 4 weeks since receipt of any investigational drug or device

          -  Have previously received any other thrombopoietic growth factor

          -  Pregnant or breast feeding

          -  Subjects of reproductive potential who are not using adequate contraceptive
             precautions, in the judgment of the investigator

          -  Known hypersensitivity to any recombinant E coli-derived product
Clinical trial NCT00192062 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, vinorelbine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria-

          -  Histological or cytological diagnosis of breast carcinoma with evidence of
             unresectable, locally recurrent, or metastatic disease. Lesions should not be amenable
             to surgery or radiation of curative intent.

          -  Presence of metastatic or local-regional recurrent disease, according to the American
             Joint Committee on Cancer (Greenz, et al, 2002).

          -  Uni-dimensionally measurable lesions with clearly defined margin that are clearly
             measurable by following methods according to computerized tomography (CT), Chest x-ray
             or clinical examination, according to RECIST criteria (Therasse, et al, 2002).

          -  No prior chemotherapy for metastatic or locoregionally recurrent disease. Prior
             adjuvant or neoadjuvant chemotherapy with Anthracyclines based regimen is mandatory.
             The time from the last dose of prior adjuvant chemotherapy and study entry must be at
             least 30 days and patients must have completely recovered from all acute chemotherapy
             related toxicities (with exception of alopecia).

          -  Prior radiotherapy must be completed at least 30 days before study entry.

          -  No concurrent hormonal therapy for MBC. Prior hormonal therapy is allowed, the time
             from the last dose of prior hormonal therapy for breast cancer to study enrollment
             must be at least 1 week.

        Exclusion Criteria -

          -  Have received treatment within the last 30 days with an investigational drug for any
             indication before study entry.

          -  Concurrent administration of other tumor therapy, including cytotoxic chemotherapy,
             surgery of cancer, radiotherapy, hormonal therapy and immunotherapy (including
             Herceptin).

          -  Active infection that in the opinion of the investigator would compromise the
             patient's ability to tolerate therapy, unless adequately treated.

          -  Pregnancy or breast-feeding.

          -  Serious concomitant disorders that would compromise the safety of the patient or
             compromise the patient's ability to complete the study, at the discretion of the
             investigator.
Clinical trial NCT00973024 (phase 2, status: terminated)
Conditions: low back pain, low back pain, recurrent
ICD codes: M54.50, M54.51, M54.59, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: jnj-42160443 3 mg, jnj-42160443 1 mg, jnj-42160443 6 mg/3mg, jnj-42160443 10 mg, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    based on lack of efficacy in pai2003, sponsor made the decision to discontinue the trial.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of chronic low back pain

        Exclusion Criteria:

          -  Pain with radiation to the extremity and with neurologic signs

          -  history within the past year of any of the following: seizure disorder

          -  intrathecal therapy and ventricular shunts, mild or moderate traumatic brain injury,
             stroke, or transient ischemic attack, meningitis

          -  History of brain injury within the past 15 years consisting of >= 1 of the following,
             or with residual sequalae suggesting transient changes in consciousness: brain
             contusion, intracranial hematoma, either unconsciousness or posttraumatic amnesia
             lasting more than 24 hours

          -  History of epilepsy or multiple sclerosis

          -  Current diagnosis of fibromyalgia, complex regional pain syndrome (including reflex
             sympathetic dystrophy or causalgia), acute spinal cord compression, bowel or bladder
             dysfunction as a result of cauda equine compression, back pain caused by secondary
             infection, or pain caused by confirmed or suspected neoplasm

          -  Any new or unresolved neurologic deficits, including progressive deficits, within 6
             months before screening
Clinical trial NCT00456599 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have cytologic or histologic confirmation of carcinoma arising in the
             pancreas.

          -  Patients must be deemed resectable or borderline resectable based on criteria in
             section 4.2 prior to registration.

          -  Patients must have an expected life expectancy of at least 12 weeks and a Zubrod
             performance status of < 2.

          -  Patients must have adequate organ function defined as follows: absolute neutrophil
             count of > 1500/mm3, platelets > 100,000/mm3, serum Cr < 1.5 mg/dl, total bilirubin <
             3.0 mg/dl with relief of biliary obstruction if present (PTC tube or endobiliary
             stent).

          -  Patients must be free of other active systemic malignancy, ongoing infection,
             including HIV infection, or any other serious uncontrolled, concomitant systemic
             disorders or psychiatric condition that would interfere with the safe delivery of
             protocol therapy.

          -  Patients must be aware of the investigational nature of the therapy and provide
             written informed consent.

          -  Patients must have no history of previous chemotherapy for pancreatic cancer or any
             abdominal radiation therapy.

          -  Patients must not have used any investigational agent in the month before enrollment
             into the study.

        Exclusion Criteria:

          -  Patients with neuroendocrine tumors are excluded.

          -  Patients with preexisting peripheral neuropathy > grade 2 are ineligible.

          -  Pregnant or nursing women are ineligible and patients of reproductive potential must
             agree to use an effective contraceptive method during participation in this trial and
             for 6 months after trial.
Clinical trial NCT00371904 (phase 2, status: unknown status)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: rituximab, standard care
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[N+]1=C(\C=N\O)C=CC=C1
Eligibility criteria:

        Inclusion criteria:

          1. Subjects, age > 18 years

          2. Subjects receiving a single organ renal transplant from a living donor

          3. Positive T-cell and/or B-cell crossmatch by complement dependent cytotoxicity (CDC)
             and/or positive flow cytometry crossmatch with confirmed donor-specific antibodies on
             solid-phase assay at screening. Positive CDC T-cell and/or B-cell crossmatch titre
             must be less than or equal to 1:64.

          4. Subjects capable of understanding the purposes and risks of the study and who can give
             written informed consent

        Exclusion Criteria at Study Entry (4 weeks prior to transplant):

          1. Primary renal transplant lost from acute rejection less than six months prior to
             randomisation

          2. Women of childbearing potential with a positive serum or urine pregnancy test or
             nursing mothers

          3. Subjects with history of malignancy (other than non melanoma skin cancer that has been
             totally excised with no recurrence for two years)

          4. Subjects with known contraindications to treatment with rituximab

          5. Subjects with haemoglobin < 8.5 g/dL, WBC value of < 3000/mm3 or a platelet count of <
             50,000/mm3 that is unlikely to resolve prior to randomisation

          6. Subjects with a positive ABO crossmatch with donor

          7. Subjects with severe diarrhoea or other gastrointestinal disorders that might
             interfere with the ability to absorb oral medication and is unlikely to resolve prior
             to randomisation

          8. Subjects participating in another interventional clinical trial or requiring treatment
             with un-marketed investigational drugs or who would be expected to require other
             medications prohibited by the protocol

          9. Subjects who cannot be followed for the study duration

         10. Subjects with disorders or conditions that may interfere with the ability to comply
             with study procedures and/or requirements

        Additional Exclusion Criteria at Day -2 before Transplantation:

          1. All exclusion criteria as at study entry

          2. Positive T- and/or B-cell CDC crossmatch at Day -2